An Open Label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

Trial Profile

An Open Label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2013

At a glance

  • Drugs Afatinib (Primary)
  • Indications Biliary cancer; Bladder cancer; Gallbladder cancer; Gastric cancer; Gynaecological cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 17 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Planned end date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 05 May 2010 Trial centres updated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top